Trial · NCT01631682
Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
NCT01631682, Phase 4, Completed, Massachusetts General Hospital; results first posted 2017-02-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders. Trials, record NCT01631682. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01631682
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
- NCT number
- NCT01631682
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 186 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Posttraumatic Stress Disorder, Anxiety Disorder
- Interventions
- Propranolol, Reactivation, Mifepristone, Intranasal oxytocin
- First posted
- 2012-06-29
- Last updated
- 2017-02-23
- Results first posted
- 2017-02-23
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline Skin Conductance Response | 48hrs | Skin conductance response (SCR) is the change in skin conductance level in response to a stimulus. We compared the SCR to a non-treated conditioned stimulus (CS+N) with the SCR to a treated conditioned stimulus (CS+R) by creating a difference score (CS+R - CS+N) for the day 3 data. Day 3 is 48 hours after the fear-conditioning procedure and serves as the primary measure of whether the treatment had an effect. SCR was measured in microSiemens; the SCR difference score reflects a change in microSiemens. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline Skin Conductance Response | 48hrs | microSiemens | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline Skin Conductance Response | Propranolol | .06 | Standard Deviation .34 | microSiemens | |
| Change From Baseline Skin Conductance Response | Reactivation With Time Delay | .17 | Standard Deviation .44 | microSiemens | |
| Change From Baseline Skin Conductance Response | Mifepristone | -1.27 | Standard Deviation 1.68 | microSiemens | |
| Change From Baseline Skin Conductance Response | Intranasal Oxytocin | -.04 | Standard Deviation .27 | microSiemens |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Propranolol | 55 | |
| Overall Study | STARTED | Reactivation With Time Delay | 66 | |
| Overall Study | STARTED | Mifepristone | 44 | |
| Overall Study | STARTED | Intranasal Oxytocin | 7 | |
| Overall Study | COMPLETED | Propranolol | 24 | |
| Overall Study | COMPLETED | Reactivation With Time Delay | 21 | |
| Overall Study | COMPLETED | Mifepristone | 13 | |
| Overall Study | COMPLETED | Intranasal Oxytocin | 5 | |
| Overall Study | NOT COMPLETED | Propranolol | 31 | |
| Overall Study | NOT COMPLETED | Reactivation With Time Delay | 45 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Mild Nausea | General disorders | Propranolol | 0 | 24 | 0 |
| other | Mild Nausea | General disorders | Reactivation With Time Delay | 0 | 21 | 0 |
| other | Mild Nausea | General disorders | Mifepristone | 2 | 13 | 2 |
| other | Mild Nausea | General disorders | Intranasal Oxytocin | 0 | 5 | 0 |
Source ClinicalTrials.gov
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Propranolol | ||
| Total, all-cause mortality | Reactivation With Time Delay | ||
| Total, all-cause mortality | Mifepristone | ||
| Total, all-cause mortality | Intranasal Oxytocin | ||
| Total, other adverse events | Propranolol | 0 | 24 |
| Total, other adverse events | Reactivation With Time Delay | 0 | 21 |
| Total, other adverse events | Mifepristone | 2 | 13 |
| Total, other adverse events | Intranasal Oxytocin | 0 | 5 |
| Total, serious adverse events | Propranolol | 0 | 24 |
| Total, serious adverse events | Reactivation With Time Delay | 0 | 21 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01631682
GET https://conductscience.org/api/trials/v1/NCT01631682/registered